|
1
|
Feng G, Valenti L, Wong VWS, Fouad YM,
Yilmaz Y, Kim W, Sebastiani G, Younossi ZM, Hernandez-Gea V and
Zheng MH: Recompensation in cirrhosis: Unravelling the evolving
natural history of nonalcoholic fatty liver disease. Nat Rev
Gastroenterol Hepatol. 21:46–56. 2024. View Article : Google Scholar
|
|
2
|
Loomba R, Friedman SL and Shulman GI:
Mechanisms and disease consequences of nonalcoholic fatty liver
disease. Cell. 184:2537–2564. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miao L, Targher G, Byrne CD, Cao YY and
Zheng MH: Current status and future trends of the global burden of
MASLD. Trends Endocrinol Metab. 35:697–707. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao L, Zhang X, Coday M, Garcia DO, Li X,
Mossavar-Rahmani Y, Naughton MJ, Lopez-Pentecost M, Saquib N,
Shadyab AH, et al: Sugar-sweetened and artificially sweetened
beverages and risk of liver cancer and chronic liver disease
mortality. JAMA. 330:537–546. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yki-Järvinen H, Luukkonen PK, Hodson L and
Moore JB: Dietary carbohydrates and fats in nonalcoholic fatty
liver disease. Nat Rev Gastroenterol Hepatol. 18:770–786. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jung S, Bae H, Song WS and Jang C: Dietary
fructose and fructose-induced pathologies. Annu Rev Nutr. 42:45–66.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ruiz-Ojeda FJ, Plaza-Díaz J, Sáez-Lara MJ
and Gil A: Effects of sweeteners on the gut microbiota: A review of
experimental studies and clinical trials. Adv Nutr. 10(Suppl 1):
S31–S48. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Magnuson BA, Carakostas MC, Moore NH,
Poulos SP and Renwick AG: Biological fate of low-calorie
sweeteners. Nutr Rev. 74:670–689. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
U.S. Food & Drug Administration (FDA):
Aspartame and other sweeteners in food. FDA; Silver Spring, MD:
2024
|
|
10
|
Spherical Insights: Global Food Sweetener
Market Insights Forecasts to 2033. Spherical Insights LLP.; Mason,
OH: 2025, https://www.sphericalinsights.com/reports/food-sweetener-market.
|
|
11
|
Suez J, Cohen Y, Valdés-Mas R, Mor U,
Dori-Bachash M, Federici S, Zmora N, Leshem A, Heinemann M,
Linevsky R, et al: Personalized microbiome-driven effects of
non-nutritive sweeteners on human glucose tolerance. Cell.
185:3307–3328.e19. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chowdhury CR and Havlik J: Beyond
sweetness: A review of the health and safety of acesulfame-K. Food
Chem. 499:1472902026. View Article : Google Scholar
|
|
13
|
Witkowski M, Nemet I, Alamri H, Wilcox J,
Gupta N, Nimer N, Haghikia A, Li XS, Wu Y, Saha PP, et al: The
artificial sweetener erythritol and cardiovascular event risk. Nat
Med. 29:710–718. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu W, Sui W, Chen S, Guo Z, Jing X, Wang
X, Wang Q, Yu X, Xiong W, Ji J, et al: Sweetener aspartame
aggravates atherosclerosis through insulin-triggered inflammation.
Cell Metab. 37:1075–1088.e7. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zani F, Blagih J, Gruber T, Buck MD, Jones
N, Hennequart M, Newell CL, Pilley SE, Soro-Barrio P, Kelly G, et
al: The dietary sweetener sucralose is a negative modulator of T
cell-mediated responses. Nature. 615:705–711. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ahmad R and Dalziel JE: G protein-coupled
receptors in taste physiology and pharmacology. Front Pharmacol.
11:5876642020. View Article : Google Scholar
|
|
17
|
Nelson G, Hoon MA, Chandrashekar J, Zhang
Y, Ryba NJ and Zuker CS: Mammalian sweet taste receptors. Cell.
106:381–390. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Behrens M: Pharmacology of TAS1R2/TAS1R3
receptors and sweet taste. The Pharmacology of Taste. Handbook of
Experimental Pharmacology. 155–175. 2022.
|
|
19
|
Neiers F, Canivenc-Lavier MC and Briand L:
What does diabetes 'taste' like? Curr Diab Rep. 16:492016.
View Article : Google Scholar
|
|
20
|
Ercin M, Gezginci-Oktayoglu S and Bolkent
S: Exendin-4 inhibits small intestinal glucose sensing and
absorption through repression of T1R2/T1R3 sweet taste receptor
signalling in streptozotocin diabetic mice. Transl Res. 246:87–101.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ubeysinghe S, Wijayaratna D, Kankanamge D
and Karunarathne A: Molecular regulation of PLCβ signaling.
Integrated Methods in Protein Biochemistry: Part C. Methods in
Enzymology. 17–52. 2023.
|
|
22
|
Pawlak M, Lefebvre P and Staels B:
Molecular mechanism of PPARα action and its impact on lipid
metabolism, inflammation and fibrosis in non-alcoholic fatty liver
disease. J Hepatol. 62:720–733. 2015. View Article : Google Scholar
|
|
23
|
Gross B, Pawlak M, Lefebvre P and Staels
B: PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev
Endocrinol. 13:36–49. 2017. View Article : Google Scholar
|
|
24
|
Chang E, Zhu Y, Wei W, Huai J, Lv T, Lou Y
and Zhou X: Chiglitazar, a PPAR pan-agonist: Impacts on type 2
diabetes mellitus and multi-system metabolic regulation-a review.
Biomed Pharmacother. 193:1188502025. View Article : Google Scholar
|
|
25
|
Palacios Girón KM, Hernandez Nazara ZH,
Maldonado-González M, Martínez-López E, Sánchez Muñoz MP, Bautista
López CA, Aguiñaga MSA, Dominguez-Rosales JA, Vargas-Guerrero B and
Ruíz-Madrigal B: Role of ChREBP-PPARα-FGF21 axis in metabolic
dysfunction of MASLD. Int J Mol Sci. 26:114252025. View Article : Google Scholar
|
|
26
|
Sheetz MJ and King GL: Molecular
understanding of hyperglycemia's adverse effects for diabetic
complications. JAMA. 288:2579–2588. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reagan-Shaw S, Nihal M and Ahmad N: Dose
translation from animal to human studies revisited. FASEB J.
22:659–661. 2008. View Article : Google Scholar
|
|
28
|
Hua H, Dai M, Luo Y, Lin H, Xu G, Hu X, Xu
L, Zhang H, Tang Z, Chang L, et al: Basal PPARα inhibits bile acid
metabolism adaptation in chronic cholestatic model induced by
α-naphthylisothiocyanate. Toxicol Lett. 300:31–39. 2019. View Article : Google Scholar
|
|
29
|
Luo J, Yan Z, Dai M, Xu L, Zhang H, Xi Y,
Yang J and Liu A: Down-regulation of hepatic CLOCK by PPARα is
involved in inhibition of NAFLD. J Mol Med (Berl). 101:139–149.
2023. View Article : Google Scholar
|
|
30
|
Wang X, Luo J, Lu Z, Fang S, Sun M, Luo W,
Shen J, Liu A and Ye H: Therapeutic effect of fenofibrate for
non-alcoholic steatohepatitis in mouse models is dependent on
regime design. Front Pharmacol. 14:11904582023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kojima I and Nakagawa Y: The role of the
sweet taste receptor in enteroendocrine cells and pancreatic
β-cells. Diabetes Metab J. 35:451–457. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
33
|
Laviada-Molina H, Molina-Segui F,
Pérez-Gaxiola G, Cuello-García C, Arjona-Villicaña R,
Espinosa-Marrón A and Martinez-Portilla RJ: Effects of nonnutritive
sweeteners on body weight and BMI in diverse clinical contexts:
Systematic review and meta-analysis. Obes Rev. 21:e130202020.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Allende DS, Gawrieh S, Cummings OW, Belt
P, Wilson L, Van Natta M, Behling CA, Carpenter D, Gill RM, Kleiner
DE, et al: Glycogenosis is common in nonalcoholic fatty liver
disease and is independently associated with ballooning, but lower
steatosis and lower fibrosis. Liver Int. 41:996–1011. 2021.
View Article : Google Scholar :
|
|
35
|
Hindmarsh JT, Kilby D and Wiseman G:
Effect of amino acids on sugar absorption. J Physiol. 186:166–174.
1966. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mace OJ, Affleck J, Patel N and Kellett
GL: Sweet taste receptors in rat small intestine stimulate glucose
absorption through apical GLUT2. J Physiol. 582:379–392. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Korenfeld N, Charni-Natan M, Bruse J,
Goldberg D, Marciano-Anaki D, Rotaro D, Gorbonos T,
Radushkevitz-Frishman T, Polizzi A, Nasereddin A, et al: Repeated
fasting events sensitize enhancers, transcription factor activity
and gene expression to support augmented ketogenesis. Nucleic Acids
Res. 53:gkae11612025. View Article : Google Scholar :
|
|
38
|
Kim H, Zheng Z, Walker PD, Kapatos G and
Zhang K: CREBH maintains circadian glucose homeostasis by
regulating hepatic glycogenolysis and gluconeogenesis. Mol Cell
Biol. 37:e00048–17. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kersten S, Seydoux J, Peters JM, Gonzalez
FJ, Desvergne B and Wahli W: Peroxisome proliferator-activated
receptor alpha mediates the adaptive response to fasting. J Clin
Invest. 103:1489–1498. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee B, Ghumman U, Pedicone LD, Aldana AG
and Lawitz E: Prospects of late-stage development agents in the
treatment of metabolic dysfunction-associated steatohepatitis. Clin
Mol Hepatol. 31:1167–1196. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tan Y and Pang X: Olfactory-gustatory
cross-modal integration: Mechanisms of aroma-induced sweetness
enhancement, sensory evaluation methodologies, neuroimaging
evidence and advances in influencing factors. J Adv Res.
S2090-1232(25)00745-32025.Epub ahead of print. PubMed/NCBI
|
|
42
|
Kawano T, Inokuchi J, Eto M, Murata M and
Kang JH: Activators and inhibitors of protein kinase C (PKC): Their
applications in clinical trials. Pharmaceutics. 13:17482021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Domingues N, Pires J, Milosevic I and
Raimundo N: Role of lipids in interorganelle communication. Trends
Cell Biol. 35:46–58. 2025. View Article : Google Scholar
|
|
44
|
Sarmento MJ, Llorente A, Petan T, Khnykin
D, Popa I, Nikolac Perkovic M, Konjevod M and Jaganjac M: The
expanding organelle lipidomes: Current knowledge and challenges.
Cell Mol Life Sci. 80:2372023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ulch BA, Clews AC, Reisiger CA, Zhu LH,
Mullen RT, Kimber MS and Xu Y: Properties and biochemistry of
phosphatidylcholine: Diacylglycerol cholinephosphotransferase. Prog
Lipid Res. 101:1013612025.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Katan M and Cockcroft S: Phospholipase C
families: Common themes and versatility in physiology and
pathology. Prog Lipid Res. 80:1010652020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Finck BN, Lehman JJ, Leone TC, Welch MJ,
Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD and
Kelly DP: The cardiac phenotype induced by PPARalpha overexpression
mimics that caused by diabetes mellitus. J Clin Invest.
109:121–130. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Montaigne D, Butruille L and Staels B:
PPAR control of metabolism and cardiovascular functions. Nat Rev
Cardiol. 18:809–823. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Shu Y, Hassan F, Ostrowski MC and Mehta
KD: Role of hepatic PKCβ in nutritional regulation of hepatic
glycogen synthesis. JCI Insight. 6:e1490232021. View Article : Google Scholar
|
|
50
|
Zheng ZG, Xu YY, Liu WP, Zhang Y, Zhang C,
Liu HL, Zhang XY, Liu RZ, Zhang YP, Shi MY, et al: Discovery of a
potent allosteric activator of DGKQ that ameliorates
obesity-induced insulin resistance via the sn-1,2-DAG-PKCε
signaling axis. Cell Metab. 35:101–117.e11. 2023. View Article : Google Scholar
|
